SEC Form 4 · accession 0001209191-16-131351
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Jun 30, 2016
Accepted (ET)
Jul 5, 2016 · 9:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2016 | J | 749 | $11.56 | A | 30,691 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on June 30, 2016 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mrs. Silvernail purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the year ended December 31, 2016.